NCT05172011
Understanding the Long-term Impact of COVID on Children and Families
At risk: Primary completion moved at least 1 year 8 months later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 11 versions: 8 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Apr 1, 2027 to Dec 31, 2028 Show 4 more changesShow less
- Eligibility criteria expanded, about 50 words
- Study completion pushed from May 23, 2027 to Sep 30, 2029
- Site details revised at 13 of 65 sites
- Publications: details revised at 3 of 3 entries
Notable Primary completion date: Apr 1, 2025 to Apr 1, 2027v8 Show 4 more changesShow less
- Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 39000 to confirmed 15028
- Study completion date: May 23, 2025 to May 23, 2027
- Site details revised at 65 of 65 sites
- Minor Enrollment target: 40000 to 39000v7
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 72 to 65
- Start date changed from estimate of Feb 14, 2022 to Mar 1, 2022
- Minor Study sites: 71 to 72
- Start date: Jan 18, 2022 to Feb 14, 2022
Show 2 earlier versionsHide 2 earlier versions
- Minor Study sites: 69 to 71v3
- Minor Study sites: 45 to 69v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Arms and interventions
SARS-CoV-2 infected children and young adults with and without current or prior PASC-like symptoms, including infected individuals with history of multisystem inflammatory syndrome in children (MIS-C), and infants born in the context of maternal SARS-CoV-2 infection during pregnancy
SARS-CoV-2 uninfected children and infants born to uninfected mothers
Newly SARS-CoV-2 infected individuals (≤4 weeks since onset of symptoms or positive laboratory testing)
Contemporaneous SARS-CoV-2 uninfected individuals selected from the same population as newly SARS-CoV-2 infected individuals
Post-acute infected individuals (\>4 weeks after initial symptoms or positive laboratory testing) in the extant, clinical and de novo cohorts, including infants born in the context of maternal SARS-CoV-2 infection during pregnancy, will be enrolled 1-24 months after initial SARS-CoV-2 infection.
Uninfected individuals will be derived from a similar population with respect to age, sex, race and ethnicity, geographic origin, sociodemographics, and time of enrollment as the infected individuals.
Individuals with history of myocarditis after receiving COVID-19 vaccine.
The primary caregiver of the child or young adult may optionally participate in the study.
If the primary caregiver is a biological parent, the other biological parent may optionally participate in the study
Sites
65 sites in 1 country